Skip to main content
Equibles
ARTL logo

ARTL · Artelo Biosciences, Inc.

Track ARTL — free

Use ARTL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.09 -0.27 (-4.25%)
Rebalance outlook locked
Market Cap
$3.25M
Shares
510,563

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-08-27 Artelo Biosciences Announces Reverse Stock Split Event
2026-08-20 Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 Event
2026-08-17 Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies Event
2026-08-17 Investor Presentation - August 2026 Presentation
2026-08-13 Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results Event
2026-08-10 Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma Event
2026-07-22 New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition Event
2026-07-17 2026 Annual Meeting of Stockholders Shareholder meeting
2026-07-16 Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions Event
2026-07-14 Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 Shareholder meeting
2026-07-13 Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy Event
2026-07-01 Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury Event
2026-06-30 Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 Event
2026-06-29 Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 Event
2026-06-10 Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success Event
2026-06-01 Investor Presentation - June 2026 Presentation
2026-05-14 Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results Event

Source: https://artelobio.com/investors/

Key facts CIK 1621221 CUSIP 04301G706 13F (30d) 11 filings 11 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)